Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Comment by Boomskidon Dec 30, 2022 1:51pm
146 Views
Post# 35197386

RE:RE:OttawaPeter's Post - An Informed Post Mortem

RE:RE:OttawaPeter's Post - An Informed Post MortemIt wouldn't surprise me if Bioasis attempts to distract shareholders by various methods. One thing that Colwell's GD and Dr. Deborah Rathjen are not doing is responding to emails, I'm being informed by shareholders. They're probably not taking calls, either. They should have been open for business this week, holidays notwithstanding.

They could soon try some stuff to deflect and obfuscate. And if the deal falls through, then they'll sound like the Wicked Witch of The West. 

It's a good bet that all of the players are watching this forum. It's the only place where shareholder opinions are being expressed. 

How could they think they would get any love from shareholders over this deal? 

Why did GD even try to speak to the deal? Why did they hold the roadshows and webinar?

It's like they didn't know or understand the fine print. Or they didn't want shareholders to know and understand the fine print.

Like I've said, I haven't seen anything that would prevent certain bad things from happening. But there were certain bad things done, like removing the major value centres of xB3 from all recent documents when promotion was so badly needed. Hunter syndrome can be presented however they want, even as the primary Bioasis program, but all it does is emphasize the removal of most xB3 things from public exposure. Those things were imprtant enough to Bioasis and shareholders that it took a 55 page presentation to cover it all - before the Cresence stuff came along!

The revealing of Ellipses was very suspicious, both its leaking and its inclusion in a presentation meant for people other than shareholders. The statement that Bioasis says things related to Ellipses have changed, or however they phrased it, was very predictable. 

If the regulators, both exchange and securities commissions, get involved, I would certainly welcome that. I'm ready for a lot on that front.

I have no care for any accusations or threats that might come my way. I would be freed from my nondisclosure agreements if they come for me. 

One thing that could come out of it all would be who the behind-the-scenes supporters have been in the fiasco of the last two years. I have my list.

For me, it's a blessing to have avoided contact with Bioasis for the last two and a half years. Nothing from them, absolutely nothing.

All I have are opinions about possibilities, what things might mean. The lack of disclosure that I have been complaining about for the last almost two years is a double-edged sword. Yes, things are hidden, but things are also happening that people need to understand. The lack of disclosure means that watchers and stakeholders have an incredibly wide scope of possible answers to questions, and from that, new questions without answers being asked, and not answered.

Poor disclosure leaves the company wide open to outrageous conjectuere if the few known facts don't eliminate the conjecture and it's resulting ocnjectures.

It's a self-inflicted wound.

jd
<< Previous
Bullboard Posts
Next >>